GH

Guardant Health, Inc.

Healthcare · USD

Set alert

Price alert · GH

All alert types
178.80 USD -6.51 -3.51%
As of Oct 30, 2026 Extended hours 178.90 +0.06%
Bid
178.78 × 2
Ask
178.82 × 2
175.44 Day range 185.65
78.60 52-week range 187.22
YTD
+75.05%
1 year
+93.49%
Open
182.48
Prev close
185.31
Mkt cap
23.99B
Vol
1.50M
Avg vol
1.94M
EPS
-3.50
P/E
0.00
Div yield
0.00%
More statistics
Low
175.44
High
185.65
Forward P/E
-471.56
Beta
1.58
Short ratio
6.12
Inst. own
100.98%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
169.49
200-d avg
130.15
1y target
202.24

5D chart

Chart tools
Interval
GH five-day price chart168.7173.1177.4181.7186.0Oct 26Oct 27Oct 28Oct 29Oct 30

Discussion (4)

Sign in to join the discussion

Brett Pickman GH 3 years ago #1

$GH very interesting ! Did reportedly cross minimum thresholds required by Medicare and Medicaid.

Riley Gallagher GH 3 years ago #2

Trading comes with a lot of benefits.I was skeptical and scared of loosing my savings but I'm glad I took the bold step that is now favoring me and my education, visit her Facebook page Magdalena J Gabriel, if you which to take advantage of her work ✅?..

Beautiful Vacations By Scotty GH 6 years ago #4

FDA Approves First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic Test

Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC). This is the first approval to combine two technologies — NGS and liquid biopsy — in one diagnostic test in order to guide treatment decisions.

“Approval of a companion diagnostic that uses a liquid biopsy and leverages next-generation sequencing marks a new era for mutation testing,” said Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health. “In addition to benefitting from less invasive testing, patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, rather than one biomarker at a time, which can translate to decreased wait